[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100479897":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":35,"locations":44,"responsibleParty":197,"collaborators":199,"id":205,"slug":206,"hasResults":207,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":207,"sex":213,"minAge":214,"maxAge":26,"enrollmentInfo":215,"targetDuration":26,"studyType":218,"phases":219,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":235},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Besancon","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental Arm (Arm A)","EXPERIMENTAL","Atezolizumab + Bevacizumab + UCPVax",[13,14,15],"Drug: Atezolizumab","Drug: Bevacizumab","Drug: UCPVax",{"label":17,"type":6,"description":18,"interventionNames":19},"Control Arm (Arm B)","Atezoliumab + Bevacizumab",[13,14],[21,27,31],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Atezolizumab","1200 mg IV every 3 weeks until disease progression or unacceptable toxicity",[17,9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Bevacizumab","15 mg\u002Fkg IV every 3 weeks until disease progression or unacceptable toxicity",[17,9],{"type":22,"name":32,"description":33,"armGroupLabels":34,"otherNames":26},"UCPVax","UCPVax vaccine (combined with Montanide ISA51 as adjuvant) at 0.5 mg subcutaneously",[9],[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Borg Christophe, Pr","CONTACT","+33 3 81 47 99 99","xtoph.borg@gmail.com",{"name":42,"role":38,"phone":26,"phoneExt":26,"email":43},"Angélique VIENOT, Dr","a3vienot@chu-besancon.fr",[45,60,71,82,93,104,115,126,138,149,157,165,173,184],{"facility":46,"status":47,"city":48,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"CHU de Besançon","RECRUITING","Besançon","France","FR",{"type":52,"coordinates":53},"Point",[54,55],6.01815,47.24878,{"lat":55,"lon":54},[58],{"name":59,"role":38,"phone":26,"phoneExt":26,"email":26},"Christophe BORG, Pr",{"facility":61,"status":47,"city":62,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"CH William Morey","Chalon-sur-Saône",{"type":52,"coordinates":64},[65,66],4.85372,46.78112,{"lat":66,"lon":65},[69],{"name":70,"role":38,"phone":26,"phoneExt":26,"email":26},"Pierre Verdier-Davioud, Dr",{"facility":72,"status":47,"city":73,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Hôpital Henri Mondor","Créteil",{"type":52,"coordinates":75},[76,77],2.46569,48.79266,{"lat":77,"lon":76},[80],{"name":81,"role":38,"phone":26,"phoneExt":26,"email":26},"Hélène REGNAULT, Dr",{"facility":83,"status":47,"city":84,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Centre Georges François Leclerc","Dijon",{"type":52,"coordinates":86},[87,88],5.01391,47.31344,{"lat":88,"lon":87},[91],{"name":92,"role":38,"phone":26,"phoneExt":26,"email":26},"François GHIRINGHELLI, Pr",{"facility":94,"status":47,"city":95,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Hôpital Nord Franche-Comté","Montbéliard",{"type":52,"coordinates":97},[98,99],6.79823,47.50957,{"lat":99,"lon":98},[102],{"name":103,"role":38,"phone":26,"phoneExt":26,"email":26},"Serge FRATTE, Dr",{"facility":105,"status":47,"city":106,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"CHU de Montpellier","Montpellier",{"type":52,"coordinates":108},[109,110],3.87635,43.61093,{"lat":110,"lon":109},[113],{"name":114,"role":38,"phone":26,"phoneExt":26,"email":26},"Eric ASSENAT, Pr",{"facility":116,"status":47,"city":117,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"CH de Mulhouse","Mulhouse",{"type":52,"coordinates":119},[120,121],7.32866,47.75205,{"lat":121,"lon":120},[124],{"name":125,"role":38,"phone":26,"phoneExt":26,"email":26},"Stephanie HUSSON-WETZEL, Dr",{"facility":127,"status":128,"city":129,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Institut de Cancérologie de l'Ouest","NOT_YET_RECRUITING","Nantes",{"type":52,"coordinates":131},[132,133],-1.55336,47.21725,{"lat":133,"lon":132},[136],{"name":137,"role":38,"phone":26,"phoneExt":26,"email":26},"Amélie MALLET, Dr",{"facility":139,"status":128,"city":140,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"Centre Hospitalier Paris St Joseph","Paris",{"type":52,"coordinates":142},[143,144],2.3488,48.85341,{"lat":144,"lon":143},[147],{"name":148,"role":38,"phone":26,"phoneExt":26,"email":26},"Eric RAYMOND, Pr",{"facility":150,"status":47,"city":140,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":151,"geoPoint":153,"contacts":154},"Groupe Hospitalier Paris Salpetrière",{"type":52,"coordinates":152},[143,144],{"lat":144,"lon":143},[155],{"name":156,"role":38,"phone":26,"phoneExt":26,"email":26},"Manon ALLAIRE, Dr",{"facility":158,"status":47,"city":140,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":159,"geoPoint":161,"contacts":162},"Hôpital BEAUJON",{"type":52,"coordinates":160},[143,144],{"lat":144,"lon":143},[163],{"name":164,"role":38,"phone":26,"phoneExt":26,"email":26},"Mohamed BOUATTOUR, Dr",{"facility":166,"status":47,"city":140,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":167,"geoPoint":169,"contacts":170},"Institut Mutualiste Montsouris",{"type":52,"coordinates":168},[143,144],{"lat":144,"lon":143},[171],{"name":172,"role":38,"phone":26,"phoneExt":26,"email":26},"Emilie SOULARUE, Dr",{"facility":174,"status":128,"city":175,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"CHU de Poitiers","Poitiers",{"type":52,"coordinates":177},[178,179],0.34348,46.58261,{"lat":179,"lon":178},[182],{"name":183,"role":38,"phone":26,"phoneExt":26,"email":26},"Valentin ROLLE, Dr",{"facility":185,"status":47,"city":186,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"Hôpital Paul Brousse","Villejuif",{"type":52,"coordinates":188},[189,190],2.35992,48.7939,{"lat":190,"lon":189},[193,195],{"name":194,"role":38,"phone":26,"phoneExt":26,"email":26},"Pascal HAMMEL, Dr",{"name":196,"role":38,"phone":26,"phoneExt":26,"email":26},"Olivier ROSMORDUC, Dr",{"type":198,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[200,202],{"name":201,"class":6},"GERCOR - Multidisciplinary Oncology Cooperative Group",{"name":203,"class":204},"PRODIGE","UNKNOWN","100479897","phase-2-evaluation-of-the-interest-to-combine-a-cd4-th1-inducer-cancer-vaccine-derived-from-telomerase-and-atezolizumab-plus-bevacizumab-in-unresectable-hepatocellular-carcinoma-100479897",false,"NCT05528952","Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: a Proof of Concept Randomized Phase II Study (TERTIO - Prodige 82)","TERTIO","Main inclusion Criteria:\n\n1. Signed informed consent\n2. Histologically confirmed hepatocellular carcinoma\n3. Locally advanced, metastatic, or unresectable disease\n4. Patient who had not previously received systemic anti-cancer treatment\n5. Age ≥ 18 years\n6. Measurable disease defined according to mRECIST guidelines (Note: Previously irradiated lesions can be considered as measurable disease only if disease progression has been unequivocally documented at that site since radiation.)\n7. Patients who have received previous chemoembolization, radioembolization and\u002For radiotherapy should have recovered from any treatment related toxicity, to a level of ≤ grade 1 (according to National Cancer Institute \\[NCI\\] common terminology criteria for adverse events, version 5 (CTCAE v5) with the exception of Grade 2 alopecia\n8. Performance status \\\u003C 2\n9. Child-Pugh Class A status\n10. BCLC C stage or BCLC B stage not eligible to loco-regional therapy according to the Barcelona Clinic Liver Cancer (BCLC) staging system\n\nMain exclusion Criteria:\n\nNon-eligible to a clinical trial:\n\n1. Patients previously exposed to anti-tumor immunotherapy as anti-PD-1, anti-PD-L1, or anti-CTLA4 agent or any immune therapy.\n2. Diagnosis of additional malignancy within 3 years prior to the inclusion with the exception of curatively treated basal cell carcinoma of the skin and\u002For curatively resected in situ cervical or breast cancer\n3. Patient with any medical or psychiatric condition or disease, which would make the patient inappropriate for entry into this study\n4. Current participation in a study of an investigational agent or in the period of exclusion\n5. Patient under guardianship, curatorship or under the protection of justice\n\n   Cancer-specific exclusion criteria:\n6. Know fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC\n7. Uncontrolled pleural effusion, pericardial effusion, ascites or symptomatic fistula\n8. Uncontrolled tumor-related pain: exposing patients to risk of exposure to corticoids or iterative hospitalizations. Symptomatic lesions amenable to palliative radiotherapy should be treated prior to inclusion. Patients should be recovered from the effects of radiation. There is no required minimum recovery period\n9. Known active central nervous system metastases and\u002For carcinomatous meningitis. Subject with previously treated brain metastases and with radiological and clinical stability are allowed\n\n   Non-eligible to treatment:\n10. History of encephalopathy\n11. Prior bleeding event due to untreated or incompletely treated esophageal and\u002For gastric varices within 6 months prior to randomization\n12. Inadequate organ functions: known cardiac failure of unstable coronaropathy, respiratory failure, or uncontrolled infection or another life-risk condition","ALL","18 Years",{"count":216,"type":217},105,"ESTIMATED","INTERVENTIONAL",[220],"PHASE2","The TERTIO trial will propose to determine the clinical interest and immunological efficacy of a treatment combining the CD4 helper T-inducer cancer anti-telomerase vaccine (UCPVax) with anti-PD-L1 therapy (atezolizumab) and bevacizumab in unresectable HCC by evaluation of the objective response rate at 6 months (randomized phase II, 10 centers, 105 patients)",[223],"Hepatocellular Carcinoma",[225],"CD4 Th1-inducer cancer vaccine","2026-03-13",{"date":228,"type":229},"2026-03-16","ACTUAL",{"date":231,"type":229},"2022-09-27",{"date":233,"type":217},"2030-02-27",{"name":5,"class":6},14]